These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 17653094

  • 1. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
    Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC.
    Oncogene; 2008 Jan 17; 27(4):490-8. PubMed ID: 17653094
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Promotion of TRAIL/Apo2L-induced apoptosis by low-dose interferon-β in human malignant melanoma cells.
    Kazaana A, Sano E, Yoshimura S, Makita K, Hara H, Yoshino A, Ueda T.
    J Cell Physiol; 2019 Aug 17; 234(8):13510-13524. PubMed ID: 30613977
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of DR4 promoter methylation on the TRAIL-induced apoptosis in lung squamous carcinoma cell.
    Wang W, Qi X, Wu M.
    Oncol Rep; 2015 Oct 17; 34(4):2115-25. PubMed ID: 26238205
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta.
    Micali OC, Cheung HH, Plenchette S, Hurley SL, Liston P, LaCasse EC, Korneluk RG.
    BMC Cancer; 2007 Mar 21; 7():52. PubMed ID: 17376236
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Increased caspase-2 activity is associated with induction of apoptosis in IFN-beta sensitive melanoma cell lines.
    Kamiya T, Okabayashi T, Yokota S, Kan Y, Ogino J, Yamashita T, Fujii N, Jimbow K.
    J Interferon Cytokine Res; 2010 May 21; 30(5):349-57. PubMed ID: 20187765
    [Abstract] [Full Text] [Related]

  • 16. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J.
    Exp Cell Res; 2007 Jul 01; 313(11):2378-88. PubMed ID: 17462628
    [Abstract] [Full Text] [Related]

  • 17. Analysis of receptors, cell surface antigens, and proteins in human melanoma cell lines resistant to human recombinant beta- or gamma-interferon.
    Gomi K, Akinaga S, Oka T, Morimoto M.
    Cancer Res; 1986 Dec 01; 46(12 Pt 1):6211-6. PubMed ID: 2430691
    [Abstract] [Full Text] [Related]

  • 18. Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines.
    Kim YI, Shin MK, Lee JW, Chung JH, Lee MH.
    Oncol Rep; 2009 Jan 01; 21(1):159-64. PubMed ID: 19082457
    [Abstract] [Full Text] [Related]

  • 19. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
    Tang X, Wu W, Sun SY, Wistuba II, Hong WK, Mao L.
    Mol Cancer Res; 2004 Dec 01; 2(12):685-91. PubMed ID: 15634757
    [Abstract] [Full Text] [Related]

  • 20. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
    Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC.
    J Immunol; 2002 Jul 15; 169(2):847-55. PubMed ID: 12097388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.